CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 397 filers reported holding CRISPR THERAPEUTICS AG in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,420,843 | +61.6% | 31,303 | +99.9% | 0.00% | 0.0% |
| Q2 2023 | $879,321 | +39.5% | 15,663 | +12.4% | 0.00% | 0.0% |
| Q1 2023 | $630,144 | -25.9% | 13,932 | -33.4% | 0.00% | 0.0% |
| Q4 2022 | $849,829 | -38.5% | 20,906 | -4.9% | 0.00% | 0.0% |
| Q1 2022 | $1,381,000 | -60.5% | 21,994 | -52.3% | 0.00% | -66.7% |
| Q4 2021 | $3,492,000 | -85.7% | 46,080 | -78.9% | 0.00% | -88.5% |
| Q3 2021 | $24,495,000 | +1086.2% | 218,844 | +1616.0% | 0.03% | +766.7% |
| Q2 2021 | $2,065,000 | -17.0% | 12,753 | -37.5% | 0.00% | -25.0% |
| Q1 2021 | $2,488,000 | – | 20,420 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |